FTC Advertising Substantiation Rules and the Limits of Claims

The Rule That Shapes Every Research Product Page

Everything Optides catalogs is sold for research use only, and that phrase does far more work than it looks like it does. It's why a product page can walk through a compound's receptor chemistry in detail and then say almost nothing about what the compound does for a person. Read enough pages in this category and the pattern gets hard to miss: technical generosity, outcome silence. It can look like evasion.

It isn't. That register is the shape left behind by federal advertising law — specifically, the Federal Trade Commission's substantiation requirements. And the core idea is narrower and stranger than "don't lie." A claim can be entirely accurate and still break the rules, because what the FTC asks is whether the person publishing it already held adequate scientific support at the moment it went out. That timing requirement, more than any list of banned words, is what limits what these pages can say.

What the FTC Act Requires Before a Claim Goes Live

Short version: you have to be holding the evidence when the claim is published. Not afterward.

Section 5 and the prior-substantiation doctrine

Section 5 of the FTC Act reaches deceptive acts and practices in commerce. The agency's working definition of deception, restated in its Health Products Compliance Guidance, is an advertisement containing "a material misrepresentation or omission that is likely to mislead consumers acting reasonably under the circumstances." Nothing in that formulation turns on intent.

The doctrine layered on top is what does most of the practical work. The Commission's Policy Statement Regarding Advertising Substantiation states the expectation that "advertisers and ad agencies have a reasonable basis for advertising claims before they are disseminated." Publishing without that basis is itself the violation. Assembling support later doesn't cure it, because the Commission regards the implicit representation — that someone checked — as material to a reader's decision in its own right.

A sliding scale, not a single threshold

How much support counts as reasonable isn't fixed. The policy statement lists the factors: "the type of claim, the product, the consequences of a false claim, the benefits of a truthful claim, the cost of developing substantiation for the claim, and the amount of substantiation experts in the field believe is reasonable."

Products bearing on human health land at the strict end of that scale on nearly every factor at once. The consequences of being wrong are physical, the benefits are the kind readers are predisposed to believe, and the relevant expert community expects clinical work. If you've wondered why language in this category runs so much more conservative than, say, consumer electronics marketing, that pile-up is the answer.

Inside "Competent and Reliable Scientific Evidence"

The phrase is a quality test, not a document count.

The definition both agencies use

The standard comes out of FTC case law and is restated in the 2022 guidance: tests, analyses, research or studies that have been "conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function to which the representation relates" and that are "generally accepted in the profession to yield accurate and reliable results."

FDA adopted the same formulation in its guidance on substantiation under section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act. The vocabulary is shared across both agencies, then, even where their jurisdictions are not.

What the 2022 revision tightened

The December 2022 Health Products Compliance Guidance replaced a 1998 document aimed narrowly at supplements, broadened coverage to health-related products generally, and dropped the word "flexible" from its description of the standard. Its most-discussed sentence says substantiation of health-related benefits "will need to be in the form of randomized, controlled human clinical testing" to meet the competent-and-reliable bar.

From there it gets specific about what makes a study count. A control group. Randomization and blinding. Statistical significance corrected across multiple outcome measures, and results that are clinically meaningful rather than merely detectable. Pre-registered outcomes, institutional review board oversight, trial registration, adequate duration, and complete reporting of every result rather than the flattering subset. The guidance also warns against searching a dataset after the fact for positive findings, which inflates the chance of a false positive.

No fixed number of trials is required. But replication carries real weight — "an additional, independently conducted study to corroborate findings provides much greater confidence in the validity of the initial results."

Express, Implied, and Establishment Claims

You answer for what a reasonable reader takes away, not for what you meant to say.

Implied claims count fully

The guidance is blunt here: "a marketer is equally responsible for the accuracy of claims suggested or reasonably implied in advertising." The analysis looks at the net impression produced by everything on a page together — body copy, headings, photographs, the product name itself — and asks "what reasonable consumers understand the advertising or marketing materials to communicate about the product."

So a page can convey a claim it never states. Adjacency does it. Imagery does it. A suggestive product name does it. And once a reasonable reader takes that message, the publisher owes evidence for it.

Establishment claims raise the bar to match your wording

Phrases like "studies show," "research proves," or "clinically tested" are express substantiation claims — they say something about the state of the evidence, not just about the product. Where a claim is express in that way, the Commission "expects the firm to have at least the advertised level of substantiation." Advertise more support than you hold and the gap is the violation.

The leading case is POM Wonderful LLC v. FTC. The D.C. Circuit affirmed the Commission's deception findings, accepted its framework of asking whether "at least a significant minority of reasonable consumers" would read the ads as making a given health claim, and declined to require consumer surveys as proof. It also agreed that touting a large research budget alongside specific benefit language amounted to an establishment claim.

The decision cut the other way in one respect. The court rejected a categorical requirement of two randomized controlled trials for every disease claim, holding the Commission had "failed adequately to justify" a blanket floor that was "more extensive than is necessary" — a First Amendment limit on restrictions of commercial speech. What survives as the practical expectation is one well-conducted trial plus corroborating evidence, weighed against the whole literature.

Why In-Vitro and Animal Data Cannot Carry a Consumer Claim

Cell-culture and animal findings are perfectly citeable as research. They just can't stand behind a statement about a person.

The predictive-value problem

FDA's position is that animal research "may provide useful background on the biological effects of a substance," while its results "often have limited or unknown value in predicting the effect of the substance in humans." The FTC takes the parallel line. Anecdote and testimony never suffice either, since a reported improvement may reflect a placebo response rather than the product.

This is why careful writing in the field insists on the observed-in-research construction. "In cell-culture work, researchers measured increased collagen synthesis" describes a finding. Collapse it to a claim about skin and you have a different sentence with a far higher evidentiary bill attached — and that gap is precisely what the agencies police. Naming the model system before the result isn't stylistic fussiness. It's the only form the underlying data can honestly take.

Totality of evidence, not your best study

FDA states there is "no general rule for how many studies, or what combination of types of evidence, is sufficient to support a claim." What matters is consistency across independently conducted work, and the obligation runs to all relevant research — including null and negative findings. Where results conflict, you need a plausible explanation; absent one, the claim likely lacks support.

Transfer is limited too. Findings on a related compound, a different formulation, or a different study population don't carry over automatically to a specific product. Our walkthrough on reading FDA warning letters sent to research peptide sellers traces the same reasoning through actual enforcement documents.

The Limits of Hedging Words and Disclaimers

Softening a sentence doesn't lower the evidence that sentence requires.

Vague qualifiers fail

The instinct when evidence is thin is to hedge. The FTC has largely closed that exit: it calls words such as "may," "promising," "preliminary," and "helps" inadequate qualifying terms, because they don't communicate genuine scientific uncertainty to an ordinary reader. Qualified claims are permitted on limited evidence — but only if the disclosure actually conveys the limitation.

Disclosures must be "clear and conspicuous — easily noticeable and understandable," in prominence comparable to the claim they qualify. Fine print doesn't satisfy that, and the operative test is unforgiving: "if a significant minority of consumers take a misleading claim from an ad despite a disclosure, the disclosure isn't sufficient." A disclaimer that flatly contradicts the main claim doesn't qualify it at all.

How that applies to research-only material

The same logic shows up on the FDA side, pointed directly at this industry. In warning letters dated March 2026, the agency held that despite "statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." The cited evidence was the sellers' own product copy — metabolic and body-composition claim language describing effects on human physiology, sitting a few scroll-lengths from the disclaimer that supposedly disowned it.

The takeaway for anyone writing in this space: the disclaimer is a floor, not a shield. Surrounding copy decides. Our explainer on what research-use-only labeling actually requires covers the labeling mechanics in more depth.

Where FDA Labeling Authority Ends and FTC Advertising Authority Begins

The same sentence gets judged differently depending on where you put it.

The division of labor

Under a long-standing memorandum of understanding between the two agencies, FDA holds primary jurisdiction over labels and labeling while the FTC takes advertising. A peer-reviewed review of the regulatory landscape lays out the consequence plainly: one sentence can be assessed under two different frameworks depending on whether it appears on a vial, on a product page, or in a paid placement.

On the FDA side the claim categories are formalized — nutrient content claims, structure/function claims describing a role in normal body function without naming a disease, and authorized health claims about disease-risk reduction. The boundary between function language and disease language is where most enforcement happens.

Intended use ties the two halves together

Both frameworks converge through a single concept. Under 21 CFR 201.128, FDA reads a product's intended use from the total context — marketing copy is evidence, not commentary. We cover that machinery in detail in our piece on the intended-use doctrine, and the downstream consequences in the primer on misbranding under the FDCA.

Which is why both agencies push toward the same editorial discipline: describe the chemistry, attribute every finding to the study that produced it, and never promise a reader an outcome.

Frequently Asked Questions

What does the FTC mean by "competent and reliable scientific evidence"?

It's a standard from FTC case law, restated in the agency's 2022 Health Products Compliance Guidance: tests, analyses, research or studies conducted and evaluated objectively by experts qualified in the relevant area, using procedures generally accepted in that profession to yield accurate and reliable results. No fixed study count attaches to it. What makes evidence competent and reliable is the match between the quality of the research and the specific thing the advertisement says.

Does the FTC legally require a randomized controlled trial for every health claim?

Not as a statute, but close to it in practice. The 2022 guidance says health-benefit substantiation will generally need to take the form of randomized, controlled human clinical testing. The D.C. Circuit in POM Wonderful LLC v. FTC rejected a blanket two-trial requirement as more restrictive than necessary under the First Amendment, leaving one well-conducted trial as the working baseline.

Can a disclaimer fix a claim the evidence does not support?

No. The FTC's position is that a disclosure fails whenever a significant minority of consumers still take the misleading message, and that a disclaimer directly contradicting the main claim doesn't qualify it at all. A 2026 FDA warning letter applied the same logic to research-only labeling: page copy describing effects on human physiology established intended use regardless of the disclaimer printed alongside it.

Why can't in-vitro or animal results support a claim aimed at consumers?

Both agencies treat them as background rather than proof. FDA's substantiation guidance says animal research may provide useful background on the biological effects of a substance while its results often have limited or unknown value in predicting the effect of that substance in humans. Cell-culture and animal data remain legitimate to describe and cite as research findings — what they can't do is stand behind a statement about what a product will accomplish for a person.

The Bottom Line

Substantiation rules aren't mainly a lie detector. They police the distance between what a page implies and what the evidence in hand can actually carry — and they measure that distance at the moment of publication, from the standpoint of an ordinary reader rather than a careful one.

Understood that way, the hedged, citation-dense register of research-compound writing stops looking like a dodge and starts looking like the only available shape. For the labeling half of the picture, start with the intended-use doctrine.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.